arrow_back Trending Legislation
Share share

New Law: Mifepristone Warning Label and Reversal Hotline

This proposed law aims to provide women with more information and support regarding a specific medication, mifepristone. It would require a warning label on the drug about potential ways to counteract its effects and establish a 24/7 hotline for women seeking such information. This could impact women's choices and access to information concerning medical abortion.
Key points
Drug manufacturers would need to add a warning label to mifepristone, stating that its effects might be counteracted by natural progesterone to increase fetal survival.
A new, free, 24-hour hotline would be created to offer support and information to women interested in reversing the effects of mifepristone.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Second Chance for Moms Act
Print number: HR 7823
Sponsor: Rep. Miller, Mary E. [R-IL-15]
Process start date: 2024-03-26
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about New Law: Mifepristone Warning Label and Reversal Hotline

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 7823.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-26.

What are the main provisions?

Key points include:

  • Drug manufacturers would need to add a warning label to mifepristone, stating that its effects might be counteracted by natural progesterone to increase fetal survival.
  • A new, free, 24-hour hotline would be created to offer support and information to women interested in reversing the effects of mifepristone.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller, Mary E. [R-IL-15].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-13.

Analysis and Potential Impact of HR 7823

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health